Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 4/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | PTPRB | P23467 | 2/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17646690 | 0.86 | CA2 (0.56) | CA1CA2PI4KBPTPRBSIRT1 | |
| SCHEMBL2600848 | 0.78 | PI4KB (0.42) | CA1CA2PI4KBLCKGSK3B | |
| SCHEMBL21705628 | 0.78 | LCK (0.41) | CA1CA2PI4KBLCKATR | |
| SCHEMBL27174917 | 0.77 | PHGDH (0.38) | CA1CA2CCNA2CDK2CCNA1 | |
| SCHEMBL22031128 | 0.77 | CA1 (0.39) | CA1CA2PI4KBLCKATR | |
| SCHEMBL29076598 | 0.77 | CA1 (0.39) | CA1CA2PI4KBLCKCCNA2 | |
| SCHEMBL20557380 | 0.77 | PI4KB (0.39) | CA1CA2PI4KBLCKATR | |
| SCHEMBL26678642 | 0.75 | PI4KB (0.38) | CA1CA2PI4KBLCKATR | |
| SCHEMBL31340978 | 0.75 | SREBF2 (0.42) | CCNA2CDK2CCNA1CDK5CDK5R1 | |
| SCHEMBL24044235 | 0.74 | CDK5 (0.44) | CA1CA2PI4KBLCKCCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4573088-A1 | HETEROCYCLE RBM39 MODULATORS | Recursion Pharmaceuticals, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20240092770-A1 | Heterocycle RMB39 Modulators | RECURSION PHARMACEUTICALS, INC. | 2024-03-21 | — | — | US | disclosed |
| WO-2024039689-A1 | HETEROCYCLE RBM39 MODULATORS | RECURSION PHARMACEUTICALS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092770-A1 | Heterocycle RMB39 Modulators | PRMT9, RCC2, RBBP9 | CA1 4867/4885CA2 4825/4885PI4KB 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.